<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016778</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-G5-21</org_study_id>
    <nct_id>NCT05016778</nct_id>
  </id_info>
  <brief_title>A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma</brief_title>
  <official_title>A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai OriginCell Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability,&#xD;
      cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple&#xD;
      myeloma subjects who have failed the standard treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limited toxicity (DLT)</measure>
    <time_frame>From date of initial treatment to Day 28 post GPRC5D CAR-T infusion.</time_frame>
    <description>Dose limited toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AE and SAE</measure>
    <time_frame>From admission to the end of the follow-up, up to 2 years</time_frame>
    <description>Adverse event and serious adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of CAR-T cells</measure>
    <time_frame>From admission to the end of the follow-up, up to 2 years</time_frame>
    <description>In peripheral blood and bone marrow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate, ORR</measure>
    <time_frame>In 3 months of GPRC5D CAR-T cell infusion</time_frame>
    <description>Proportion of subjects with complete or partial remission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate, DCR</measure>
    <time_frame>From Day 28 GPRC5D CAR-T infusion up to 2 years</time_frame>
    <description>The percentage of patients with remission and stable disease after treatment in the total evaluable cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission, DOR</measure>
    <time_frame>24 months post GPRC5D CAR-T cells infusion</time_frame>
    <description>The time from the first assessment of remission or partial remission of the tumor to the first assessment of disease progression or death from any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, PFS</measure>
    <time_frame>24 months post GPRC5D CAR-Tcells infusion</time_frame>
    <description>The time from cell reinfusion to the first assessment of tumor progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival, OS</measure>
    <time_frame>From GPRC5D CAR-T infusion to death，up to 2 years</time_frame>
    <description>The time from the cell reinfusion to death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a open label, single arm clinical trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GPRC5D-CAR-T</intervention_name>
    <description>After enrollment, subjects complete the PBMC apheresis, then complete the Lymphocyte clearance, and then receive the dose climbing test: 1×10e6/kg，3×10e6/kg，6×10e6/kg.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject can understand and have the ability to sign an informed consent form;&#xD;
&#xD;
          2. Male or female subjects, aged 18-75 years;&#xD;
&#xD;
          3. The expected survival period is not less than 12 weeks;&#xD;
&#xD;
          4. ECOG score ≤ 2 ;&#xD;
&#xD;
          5. Diagnosed as multiple myeloma according to the IMWG standard in 2018;&#xD;
&#xD;
          6. The expression of GPRC5D in bone marrow plasma cells is more than 20%, or it is&#xD;
             positive in tumor tissue by immunohistochemistry. One of the following criteria must&#xD;
             be detected:&#xD;
&#xD;
               1. If IgG type MM, serum M protein ≥10g/L; if IgA, IgD, IgE or IgM type MM, serum M&#xD;
                  protein ≥5g/L;&#xD;
&#xD;
               2. Or urine M protein level ≥200mg/24h;&#xD;
&#xD;
               3. Or light chain type MM, serum free light chain (sFLC) ≥ 100mg / L and K/ λ FLC&#xD;
                  ratio is abnormal;&#xD;
&#xD;
               4. Or there are extramedullary lesions;&#xD;
&#xD;
          7. Subjects who have received at least 3 different mechanism drugs (including&#xD;
             chemotherapy, protease inhibitors, immunosuppressive agents, etc.) have failed&#xD;
             treatments, or have progressed or recurred during the last treatment or within 6&#xD;
             months after the end of treatment ;&#xD;
&#xD;
          8. Lung function is normal, and oxygen saturation is greater than 92%;&#xD;
&#xD;
          9. No heart disease or coronary heart disease, echocardiogram showed normal diastolic&#xD;
             function, left ventricular ejection fraction (LVEF) ≥50%, and no serious arrhythmia;&#xD;
&#xD;
         10. Liver function: TBIL&lt;3×ULN, AST&lt;2.5×ULN, ALT&lt;2.5ULN;&#xD;
&#xD;
         11. Renal function: creatinine clearance rate (estimated by Cockcroft Gault formula) ≥ 30&#xD;
             mL/min;&#xD;
&#xD;
         12. The blood routine meets the following standards:&#xD;
&#xD;
               1. Lymphocyte count&gt;0.5×10e9/L;&#xD;
&#xD;
               2. Neutrophils ≥1.0×10e9/L;&#xD;
&#xD;
               3. Hemoglobin ≥80g/L;&#xD;
&#xD;
               4. Platelet ≥75×10e9/L&#xD;
&#xD;
         13. From the use of study drug to 2 years after treatment, male subjects or female&#xD;
             subjects of childbearing age must agree and be able to take effective contraceptive&#xD;
             measures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding;&#xD;
&#xD;
          2. HBsAg or HBcAb are positive, and the quantitative detection of HBV DNA in peripheral&#xD;
             blood is more than 100 copies / L; HCV antibody and HCV RNA in peripheral blood are&#xD;
             positive; HIV antibody positive; Syphilis antibody is positive in the first screening;&#xD;
&#xD;
          3. Any unstable systemic disease: including but not limited to unstable angina,&#xD;
             cerebrovascular accident or transient cerebral ischemia (within 6 months before&#xD;
             screening), myocardial infarction (within 6 months before screening), congestive heart&#xD;
             failure (New York Heart Association [NYHA] classification ≥ grade III), severe&#xD;
             arrhythmia with poor drug control, liver, kidney or metabolic diseases;&#xD;
&#xD;
          4. Had hypersensitivity or intolerance to any drug used in this study;&#xD;
&#xD;
          5. Patients who received anti-cancer chemotherapy or other medications within 2 weeks&#xD;
             before screening;&#xD;
&#xD;
          6. Uncontrolled malignant tumors except MM, excluding malignant tumors that received&#xD;
             radical treatment and no active disease was found within 3 years before enrollment;&#xD;
&#xD;
          7. Clinically significant central nervous system diseases, such as epilepsy,&#xD;
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, psychosis, active&#xD;
             central nervous system involvement or cancerous meningitis;&#xD;
&#xD;
          8. In the past two years, autoimmune diseases (such as Crohn's disease, rheumatoid&#xD;
             arthritis, systemic lupus erythematosus) caused damage to terminal organs, or required&#xD;
             systemic application of immunosuppressive or other drugs;&#xD;
&#xD;
          9. Severe active viral, bacterial or uncontrolled systemic fungal infections; Hereditary&#xD;
             bleeding / coagulation diseases, history of non traumatic bleeding or thromboembolism,&#xD;
             other diseases that may increase the risk of bleeding, etc;&#xD;
&#xD;
         10. Patients who received autologous hematopoietic stem cell transplantation (ASCT) within&#xD;
             8 weeks before screening, or who plan to undergo ASCT during the study period;&#xD;
&#xD;
         11. Patients received allogeneic stem cell therapy;&#xD;
&#xD;
         12. Any unsuitable to participate in this trial judged by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang He</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhang Ming ming</last_name>
    <phone>13656674208</phone>
    <email>mingmingzhang@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first affiliated hospital of medical college of zhejiang university</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, MD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>CAR-T</keyword>
  <keyword>GPRC5D</keyword>
  <keyword>Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

